PDCD1 and hepatocellular carcinoma: Another phase Ib of dose-escalation and dose-expansion study is assessing the safety and tolerability of the combination of sorafenib with spartalizumab, an anti-PD-1 mAb, in advanced HCC (NCT02988440).